This video reviews first- and second-line treatment options for patients with carcinoma of the gastroesophageal junction.
In this video, Ian Chau, MD, of Royal Marsden Hospital in London, reviews first- and second-line treatment options for patients with carcinoma of the gastroesophageal junction.
In the first-line setting, different standards for treatment duration exist around the world, including the idea of rechallenging with the same chemotherapy if a patient achieves stable disease.
In the second-line setting, Chau discusses the use of chemotherapy and ramucirumab.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer
February 18th 2024Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma
February 7th 2024Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.